Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silvercorp to Acquire Adventus Creating a Diversified Mining Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News CNS Pharmaceuticals Inc CNSP

Healthcare
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system (CNS). The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is in development for... see more

Recent & Breaking News (NDAQ:CNSP)

CNS Pharmaceuticals Provides Clinical Trial Update for Ongoing Potentially Pivotal Study with Berubicin for the Treatment of Glioblastoma Multiforme (GBM)

Accesswire August 3, 2023

CNS Pharmaceuticals (NASDAQ:CNSP) Announces Acceptance of Abstract for Poster Presentation at the 2023 SNO/ASCO CNS Cancer Conference

Accesswire July 27, 2023

CNS Pharmaceuticals to Participate in the Virtual Investor Summer Spotlight Series

Accesswire July 5, 2023

CNS Pharmaceuticals (NASDAQ:CNSP) to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest

Accesswire June 14, 2023

CNS Pharmaceuticals (NASDAQ:CNSP) Achieves Over 50% Completion of Enrollment in Potentially Pivotal Study with Berubicin for the Treatment of Glioblastoma Multiforme (GBM)

Accesswire May 25, 2023

CNS Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

Accesswire May 15, 2023

Bettina M. Cockroft, M.D., M.B.A., Pharmaceutical and Biotech Industry Veteran, Joins CNS Pharmaceuticals Board of Directors

Accesswire May 8, 2023

CNS Pharmaceuticals Investigating Potential Naked Short Selling; Retains Shareholder Intelligence Services, LLC

Accesswire May 3, 2023

CNS Pharmaceuticals to Present at the Virtual Investor Spotlight Event - Rapidly Advancing GBM Pivotal Study

Accesswire April 27, 2023

Over 100 Patients Now Enrolled in CNS Pharmaceuticals' (NASDAQ: CNSP) Potentially Pivotal Study Evaluating Berubicin for the Treatment of Glioblastoma Multiforme (GBM)

Accesswire April 10, 2023

CNS Pharmaceuticals Receives Approval from Competent Authority and Central Ethics Committee in Italy for Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM

Accesswire April 6, 2023

CNS Pharmaceuticals Reports Full Year 2022 Financial Results and Provides Corporate Update

Accesswire April 3, 2023

CNS Pharmaceuticals to Present at the Virtual Investor GBM Spotlight Event

PR Newswire March 29, 2023

CNS Pharmaceuticals Announces it Has No Exposure to Silicon Valley Bank Issues

PR Newswire March 13, 2023

CNS Pharmaceuticals Continues Momentum in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM with First Patient Enrolled in Switzerland

PR Newswire March 9, 2023

CNS Pharmaceuticals Announces First Patient Enrolled in Spain in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM

PR Newswire February 7, 2023

CNS Pharmaceuticals Announces Investigator-Initiated Phase 1b/2 Trial to be Conducted at the Pomeranian Medical University in Poland

PR Newswire January 12, 2023

JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19th

Accesswire January 11, 2023

CNS Pharmaceuticals to Present at the Virtual Investor 2023 Companies to Watch Event

PR Newswire January 5, 2023

CNS Pharmaceuticals Appoints Faith L. Charles, JD as Chair of the Board of Directors

PR Newswire January 3, 2023